Schedule of Events
Individual presenter disclosures are linked to their names in the Schedule of Events below. You may also view all presenter disclosures at once.
[M] = medical oncologist, [R] = radiation oncologist, [S] = surgeon/surgical oncologist
Wednesday, March 13, 2019
4:00 p.m. - 6:00 p.m.
Registration
Thursday, March 14, 2019
7:00 a.m. - 5:00 p.m.
Registration
7:00 a.m. - 8:00 a.m.
Continental Breakfast
7:50 a.m. - 8:00 a.m.
Day One Welcome
Jessica S. Donington, MD, New York University Cancer Center, New York [S]
8:00 a.m. - 9:15 a.m.
General Session I: Lung Cancer Screening and Diagnosis
Moderator: Nathan A. Pennell, MD, PhD, Cleveland Clinic, Cleveland [M]
- Why Has Screening Not Been More Widely Adopted?
Renda Soylemez Wiener, MD MPH, Boston University, Boston [Pulmonologist] - Radiomics and Radiogenomics in Lung Cancer Diagnosis
Ann Leung, MD, Stanford University Medical Center, Stanford, California [Radiologist] - Advanced Bronchoscopic and Targeting Techniques for Diagnosis
Jamie L. Bessich, MD, NYU Langone Laura and Isaac Perlmutter Cancer Center, New York [S] - Early Detection Using Blood and Breath Biomarkers
Peter Mazzone, MD, MPH, Cleveland Clinic, Cleveland [Pulmonologist] - Questions and Answers
Break
9:30 a.m. - 10:15 a.m.
Keynote I: Updates from the National Lung Cancer Round Table
Moderator: Ramesh Rengan, MD, PhD, University of Washington, Seattle [R]
Speaker: Ella A. Kazerooni, MD, University of Michigan, Ann Arbor, Michigan [Diagnostic Radiologist]
10:15 a.m. - 10:45 a.m.
Coffee Break
10:45 a.m. - 12:15 p.m.
Plenary Session
Moderator: Sue Yom, MD, PhD, University of California, San Francisco [R]
- 1: Improved Overall Survival with Local Consolidative Therapy in Oligometastatic Non-small Cell Lung Cancer: Results from a Cohort of 194 Patients with Synchronous Disease
Erin Corsini, MD, MD Anderson Cancer Center, Houston - 2: Upstaging in Repeat PET/CT prior to Chemoradiation in Locally Advanced NSCLC: Implications for Clinical Care
Jing Zeng, MD, University of Washington, Seattle - 3: The Impact of the Stage III Randomized Trial by Takahashi et al. on the Use of Prophylactic Cranial Irradiation (PCI) in Patients with Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Olsi Gjyshi, MD, PhD, MD Anderson Center, Houston - Discussant
Kristin Higgins, MD, Emory University, Atlanta - 4: Tumor Treating Fields Plus Chemotherapy for First-line Treatment of Malignant Pleural Mesothelioma: Final Results of the STELLAR Trial
Federica Grosso, MD, SS Antonio e Biagio General Hospital, Alessandria, Italy - 5: The Impact of Structured, Prospective Exposure to the NCCN Guidelines when Making Treatment Decisions: Improved Metrics of Guideline-Concordant Care for Patients with Non-small Cell Lung Cancer
Susan Wu, MD, University of California, San Francisco - 6: Multidisciplinary Treatment of Thymic Neuroendocrine Tumors: Evaluation of the Impact of Surgery, Chemotherapy, and Radiation
Erin Corsini, MD, MD Anderson Cancer Center, Houston - 7: Correlation of Survival Outcomes with Clinical and Molecular features in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Ruqin Chen, MB, Mayo Clinic Florida, Jacksonville, Florida - Discussant
Aaron S. Mansfield, MD, Mayo Clinic, Rochester, Minnesota [M]
12:15 p.m. - 1:15 p.m.
Lunch in the Exhibit Hall
Expert Office Hours (in Aqua 300AB, Level 3)
1:15 p.m. - 2:45 p.m.
General Session II: Early Stage Thoracic Cancers
Moderator: Jessica S. Donington, MD, New York University Cancer Center, New York [S]
- Surgical Options for Stage I NSCLC, Including Synchronous and Metachronous Primaries: Pros and Cons
Melanie Edwards, MD, St. Joseph Mercy/IHA Thoracic Surgery, Ypsilanti, Michigan [S] - Radiation Therapy Including SBRT for Stage I NSCLC – Pros and Cons
Jing Zeng, MD, University of Washington, Seattle [R] - The Medical Oncologist and Stage I NSCLC: Is There a Role for Adjuvant and/or Neoadjuvant Therapy?
Hatim Husain, MD, University of California San Diego, La Jolla, California [M] - Early Stage Tumor Board
- Questions and Answers
2:45 p.m. - 3:15 p.m.
Coffee Break
3:15 p.m. - 5:00 p.m.
General Session III: Locally Advanced Stage III Cancer
Moderator: Ramesh Rengan, MD, PhD, University of Washington, Seattle [R]
- Systemic Therapy: Induction, Consolidation, Immunotherapy
Jyoti Patel, MD, University of Chicago [M] - Does Surgery Have a Role in Stage III NSCLC?
Mark W. Onaitis, MD, UC San Diego Health, La Jolla, California [S] - Neoadjuvant or Adjuvant Radiotherapy for Stage III NSCLC?
Cecile Le Péchoux, MD, Institut de Cancérologie Gustave Roussy, Villejuif, France [R] - Definitive Chemoradiotherapy in Stage III NSCLC
Arya Amini, MD, City of Hope, Duarte, California [R] - Locally Advanced Tumor Board
- Additional panelist: Peter Mazzone, MD, MPH, Cleveland Clinic, Cleveland [Pulmonologist]
- Q&A/Discussion
5:00 p.m. - 6:00 p.m.
Poster Viewing Session and Reception
Friday, March 15, 2019
7:00 a.m. - 4:30 p.m.
Registration
7:00 a.m. - 8:00 a.m.
Continental Breakfast
7:55 a.m. - 8:00 a.m.
Day Two Welcome
Nathan A. Pennell, MD, PhD, Cleveland Clinic, Cleveland [M]
8:00 a.m. - 9:15 a.m.
General Session IV: Evaluation, Prehabilitation, ERAS, and Quality of Life
Moderator: Richard Whyte, MD, Beth Israel Deaconess Medical Center, Boston [S]
- Is My Patient Frail?
Mark K. Ferguson, MD, University of Chicago, Chicago [S] - ERAS in Lung Resection: What Non-surgeons Need To Know
Linda W. Martin, MD, MPH, FACS, FCCP, University of Virginia Health System, Charlottesville, Virginia [S] - Patient Reported Outcomes for NSCLC Therapy
Benjamin Movsas, MD, Henry Ford Health System, Detroit [R] - Supportive and End-of-Life Care
Lauren Hertan, MD, MS, Beth Israel Deaconess Medical Center, Boston [R] - Questions and Answers
9:15 a.m. - 9:30 a.m.
Break
9:30 a.m. - 10:15 a.m.
Keynote II: Opioid Use and Cancer Patients’ Pain Management
Moderator: Ravi Salgia, MD, PhD, City of Hope, Duarte, California [M]
Speaker: Eduardo Bruera, MD, FAAHPM, MD Anderson Cancer Center, Houston [M]
10:15 a.m. - 10:45 a.m.
Coffee Break
10:45 a.m. - 12:15 p.m.
Oral Abstract Session
Moderator: Melanie Edwards, MD, St. Joseph Mercy/IHA Thoracic Surgery, Ypsilanti, Michigan [S]
- 8: SABR in Early Stage NSCLC: Comparing Survival Outcomes in Adenocarcinoma and Squamous Cell Carcinoma
Stephen Abel, DO, Allegheny Health Network Cancer Institute, Pittsburgh - 9: Impact of Operability and Minimally Invasive Techniques on Post-Treatment Mortality with SBRT and Surgery in Early Stage NSCLC
William Stokes, MD, Emory University, Atlanta - 10: Stereotactic Body Radiotherapy versus Local Tumor Ablation for Early-Stage Non-Small Cell Lung Cancer
Bryan Ager, MD, University of Utah, Salt Lake City - 11: Outcomes after lung stereotactic body radiotherapy with and without pathologic confirmation
Joel Wilkie, MD, PhD, University of Michigan, Ann Arbor, Michigan - 12: Early Outcomes of Patients with Locally-Advanced Non-small Cell Lung Cancer Treated with Intensity-Modulated Proton vs. Intensity-Modulated Radiation Therapies: A Single-Institution Experience
Nathan Yu, MD, Mayo Clinic, Phoenix - 13: Treatment Allocation Modeling and Risk-Stratified Outcomes for Clinical Stage I Non-small Cell Lung Cancer Patients Receiving Surgery versus Stereotactic Body Radiation Therapy
Pamela Samson, MD, Washington University, St. Louis - 14: Local therapy for oligoprogression in NSCLC patients being treated with osimertinib
Abraham Wu, MD, Memorial Sloan Kettering Cancer Center, New York - Discussant
Megan E. Daly, MD, UC Davis Health, Sacramento, California
12:15 p.m. - 1:15 p.m.
Lunch in the Exhibit Hall
Trainee and Early-career Networking Luncheon (in Aqua Ballroom Salons DEF, Level 3)
Speakers:
- Ravi Salgia, MD, PhD, City of Hope, Duarte, California [M]
- Linda W. Martin, MD, MPH, FACS, FCCP, University of Virginia Health System, Charlottesville, Virginia [S]
- Sue Yom, MD, PhD, University of California, San Francisco [R]
1:15 p.m. - 2:15 p.m.
General Session V: Rare Thoracic Cancers
Moderator: Aaron S. Mansfield, MD, Mayo Clinic, Rochester, Minnesota [M]
- Mesothelioma
Shirish M. Gadgeel, MD, University of Michigan, Ann Arbor, Michigan [M] - Thymic Epithelial Tumors
Heather Wakelee, MD, Stanford University, Stanford, California [S] - Novel Imaging and Treatments in Neuroendocrine Tumors
Andrei H. Iagaru, MD, Stanford School of Medicine, Stanford, California [Nuclear Medicine Physician] - Questions and Answers
2:15 p.m. - 2:45 p.m.
Coffee Break
2:45 p.m. - 4:30 p.m.
General Session VI: Advanced Non-small Cell Lung Cancer
Moderator: Shirish M. Gadgeel, MD, University of Michigan, Ann Arbor, Michigan [M]
- Integrating Chemotherapy and Immune Therapy
Thomas Eldridge Stinchcombe, MD, Duke Cancer Institute, Durham, North Carolina [M] - Current State-of-the-Art for EGFR+ and ALK+ Patients
Heather Wakelee, MD, Stanford University, Stanford, California [M] - Emerging Targeted Therapies
Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center, New York [M] - Oligometastatic Disease – Treatment Options
Daniel R. Gomez, MD, MD Anderson Cancer Center, Houston [R] - Advanced Non-small Cell Lung Cancer Tumor Board
- Questions and Answers
Saturday, March 16, 2019
7:00 a.m. - 12:00 p.m.
Registration
7:00 a.m. - 8:00 a.m.
Continental Breakfast
7:55 a.m. - 8:00 a.m.
Day Three Welcome
Ramesh Rengan, MD, PhD, University of Washington, Seattle [R]
8:00 a.m. - 9:00 a.m.
General Session VII: What’s New in Small Cell Lung Cancer?
Moderator: Ravi Salgia, MD, PhD, City of Hope, Duarte, California [M]
- Current Radiation Management of Small Cell
Jeffrey A. Bogart, MD, State University of New York, New York [R] - Current Medical Management of Small Cell
Ticiana A. Leal, MD, University of Wisconsin, Madison, Wisconsin [M] - Emerging Approaches
Helen J. Ross, MD, Mayo Clinic, Scottsdale, Arizona [M] - Questions and Answers
9:00 a.m. - 9:15 a.m.
Break
9:15 a.m. - 10:45 a.m.
General Session VIII: Special Topics in Immunotherapy
Moderator: Sue Yom, MD, PhD, University of California, San Francisco [R]
- Radiation and Immunotherapy: The Inflammation Perfect Storm
Sean Park, MD, MS, PhD, Mayo Clinic, Rochester, Minnesota [R] - Immunotherapy and Brain Metastases
Sarah B. Goldberg, MD, MPH, Yale Cancer Center, New Haven, Connecticut [M] - Hyperprogression in Patients on Immunotherapy
Christophe Le Tourneau, MD, PhD, Institut Curie, Paris [M] - Immunotherapy Tumor Board
- Q&A/Discussion
10:45 a.m. - 11:00 a.m.
Break
11:00 a.m. - 12:00 p.m.
General Session IX: Management of Immunotherapy Toxicities
Moderator: Nathan A. Pennell, MD, PhD, Cleveland Clinic, Cleveland [M]
- Pulmonary Toxicities of Chemotherapy and Immunotherapy for NSCLC
Sandip Patel, MD, University of California San Diego, La Jolla, California - Safety of Immunotherapy in Patients with Autoimmune Disease
Martin J. Edelman, MD, Fox Chase Cancer Center, Philadelphia [M] - Toxicities of Immunotherapy Combined with Targeted Therapies
Leora Horn, MD, MSc, Vanderbilt University, Nashville, Tennessee [M] - Questions and Answers